Subscribe to this column
Clifford A. Hudis, MD, FACP, FASCO
Clifford A. Hudis, MD, FACP, FASCO, is the CEO of ASCO, executive vice chair of Conquer Cancer, the ASCO Foundation, and chair of CancerLinQ. Prior to these roles, he served as chief of the Breast Medicine Service and an attending physician at Memorial Sloan Kettering Cancer Center and as a professor in the Department of Medicine at Weill Cornell Medical College. He is a past president of ASCO. His research interests include all areas of care related to breast cancer, with a focus on the development of novel systemic therapies and prevention interventions related to obesity and inflammation. Follow Dr. Hudis on Twitter @CliffordHudis.
May 17, 2014
With the approach of our 50th Annual Meeting, ASCO is also formally launching an entirely new initiative aimed at the growing problem of obesity. This effort, funded through our Conquer Cancer Foundation, is meant to help us all confront obesity which is a risk for many common cancers and also a...
Mar 27, 2014
As you read this, our 50th Annual Meeting is rapidly approaching. Tens of thousands of travelers are planning their time in Chicago, and hundreds of presenters and discussants are finalizing their posters and slides while many more ASCO volunteers and staff are making final preparations to...
Jan 27, 2014
The approach of ASCO’s Annual Meeting—where we will celebrate the 50th year since our founding in 1964—brings excitement and anticipation. Your Cancer Education Committee, led by Dr. Gini Fleming, has been working hard and in collaboration with the...
Nov 12, 2013
Sometimes life and events unfold in ways that suggest the presence of planning and forethought. It is hard to be sure since, faced with randomness and coincidence, some have suggested that we have been selected through evolution to see patterns and associations even when none exist.
Oct 04, 2013
This week I had the good fortune to attend the 10th Main Meeting of the Early Breast Cancer Trialists’ Collaborative Group in Oxford, England. Known widely as “the meta-analysis” or as the “Oxford Overview,” this effort has relied on very large numbers (of randomly assigned patients) to fuel the...
Sep 02, 2013